Medscape Conference Coverage, based on selected sessions at the:
American Academy of Pain Medicine 23rd Annual Meeting
February 7 - 10, 2007, New Orleans, Louisiana
This activity is not sanctioned by, nor a part of, the American Academy of Pain Medicine.
Topic Overviews- CME/CE Highlights of American Academy of Pain Medicine 23rd Annual Meeting
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™ Nurses - 1.0 nursing contact hours (0.5 of these credits are in the area of pharmacology) Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs) - Opioid and Nonopioid Therapies for the Management of Pain
Lynn Webster, MD - New Findings in Misuse and Abuse of Medications and Addiction
Steven D. Passik, PhD - Interventional Approaches to Pain Management and Other Important Topics
David L. Caraway, MD, PhD
Expert InterviewConference SpotlightConference News- Psychiatric Factors Linked to Increased Risk for Misuse of Opioid MedicationsA new study of patients with chronic noncancer pain suggests a history of psychiatric factors, such as mood disorders, psychological problems, or psychosocial stressors, is associated with an increased risk for misuse of prescription opioids.
Medscape Medical News, March 1, 2007 - Botox Injections Possible Treatment for Refractory Headache SyndromeA new study suggests that botulinum toxin A may be helpful in treating patients with refractory headache syndrome. A retrospective review showed reduction in the number and duration of headaches in patients with chronic migraines, daily headaches, and cervicalgia headaches who had failed conventional treatment.
Medscape Medical News, February 21, 2007 - Hydromorphone in Urine Drug Tests is an Indicator of Morphine TherapyResults of a new study confirm that hydromorphone is a minor metabolite of morphine and appears on urine drug testing, suggesting it may be used to determine whether patients are compliant with therapy.
Medscape Medical News, February 14, 2007 - Pharmacogenomics and TDM May Decrease Adverse Drug ReactionsGenotyping chronic pain patients in addition to use of therapeutic drug management may improve patient outcomes by reducing adverse drug reactions, a new study suggests.
Medscape Medical News, February 13, 2007
|
Legal Disclaimer
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Academy of Pain Medicine. These materials and the related activity are not sanctioned by the American Academy of Pain Medicine or the commercial supporter of the conference and do not constitute an official part of that conference.
Copyright © 2007 Medscape.
